Journal of Clinical and Translational Pathology
DNA Methylation Biomarkers: From Precancerous Lesions to Adenocarcinoma in the Stomach and Esophagus
By Maylynn Hu and Zhongren Zhou.
Abstract
Esophageal adenocarcinoma (EAC) and gastric cancer (GC) remain major causes of cancer-related mortality worldwide, largely because of late-stage diagnosis. Barrett’s esophagus (BE) is the established precursor setting for EAC, whereas gastric intestinal metaplasia is an important precursor lesion in the intestinal-type gastric carcinogenesis pathway. Aberrant DNA methylation arises early in both pathways and may offer greater sensitivity and specificity than histology or serology alone, while also illuminating the biology of neoplastic progression. This review evaluates the evidence and translational potential of DNA methylation biomarkers in upper gastrointestinal adenocarcinoma.
Keywords
- Esophageal Cancer Research and Treatment
- Esophagus
- Adenocarcinoma
- Stomach
- DNA methylation
- Esophageal adenocarcinoma
- DNA
- Precancerous condition
- Open access
Source
Published in Journal of Clinical and Translational Pathology. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
